<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451334</url>
  </required_header>
  <id_info>
    <org_study_id>GS-01</org_study_id>
    <nct_id>NCT00451334</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement</brief_title>
  <acronym>GS</acronym>
  <official_title>Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, open label, controlled, single center study. 40 patients will be&#xD;
      recruited for the study, according to patients' inflow and meeting eligibility criteria.&#xD;
&#xD;
      Primary Goal&#xD;
&#xD;
      * To evaluate the safety of the GlucoSat technology as a non-invasive blood glucose level&#xD;
      measurement technology.&#xD;
&#xD;
      Secondary Goal&#xD;
&#xD;
      * To assess the efficacy of the GlucoSat technology as a non-invasive blood glucose level&#xD;
      measurement technology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint Parameter&#xD;
&#xD;
      â€¢ Primary study endpoint will be to establish the safety of using the GlucoSat technology as&#xD;
      a non-invasive glucose level measurement technology. Safety will be established by paucity of&#xD;
      adverse events. Adverse Events occurrence will be documented throughout the study.&#xD;
&#xD;
      Secondary Endpoint Parameters&#xD;
&#xD;
      Efficacy of the GlucoSat technology will be assessed by:&#xD;
&#xD;
        -  Proving the accuracy and precision of the GlucoSat technology by comparing the glucose&#xD;
           level measured by the GlucoSat device to the glucose level observed by any certified for&#xD;
           clinics invasive device. Inter device variability should be within 15%.&#xD;
&#xD;
        -  Patient satisfaction questionnaire.&#xD;
&#xD;
        -  Physician satisfaction will be assessed by questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female aged 18 and up.&#xD;
&#xD;
          -  Subject was diagnosed as a diabetes patient or healthy subject.&#xD;
&#xD;
          -  Subject able to comprehend and give informed consent for participation in this study.&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Patients treated with steroid.&#xD;
&#xD;
          -  Concomitant Coumadin use&#xD;
&#xD;
          -  Recent (within the last 3 months) myocardial infarction or CVA (stroke).&#xD;
&#xD;
          -  Any chronic unstable disease within the last 3 months.&#xD;
&#xD;
          -  Acute bleeding disorders.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Hepatitis B/C positive.&#xD;
&#xD;
          -  BMI&gt;37&#xD;
&#xD;
          -  Needing emergency surgery&#xD;
&#xD;
          -  Known cognitive or psychiatric disorder&#xD;
&#xD;
          -  Physician objection&#xD;
&#xD;
          -  Concurrent participation in any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shai Efrati, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna Levy, PhD</last_name>
      <phone>+972-6-388-837</phone>
      <email>hanna@qsitemed.com</email>
    </contact>
    <investigator>
      <last_name>Shai Efrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>March 22, 2007</last_update_submitted>
  <last_update_submitted_qc>March 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

